Rozerem
(Ramelteon) is the first and only prescription sleep medication that has
shown no evidence of abuse and dependence and, as a result, has not been
designated as a controlled substance by the DEA. With the exception of Rozerem
(Ramelteon), all other prescription medications indicated for insomnia are
classified as Schedule IV controlled substances by the DEA. Additionally,
Rozerem Ramelteon is the first prescription insomnia medication with a new
therapeutic mechanism of action in 35 years.
| Medication | Price | Consult | Order Now |
| 30 Pills - Rozerem 8mg Tablets | $169.00 | Free | Order Rozerem |
| 60 Pills - Rozerem 8mg Tablets | $279.00 | Free | Order Rozerem |
| 90 Pills - Rozerem 8mg Tablets | $389.00 | Free | Order Rozerem |
Rozerem (Ramelteon) is indicated for the treatment of insomnia characterized by difficulty with sleep onset.
Rozerem should not be used by patients with severe hepatic impairment, or in patients in combination with fluvoxamine. This medication has not been studied in subjects with severe sleep apnea or severe COPD and is not recommended for use in those populations. Patients should be advised to exercise caution if they consume alcohol in combination with this medication. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. As a result, healthcare professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. This medication has not been studied in children or adolescents, and the effects in these populations are unknown.
Rozerem (Ramelteon) should be taken within 30 minutes before going to bed and activities should be confined to those necessary to prepare for bed. this medication should not be taken with or immediately after a high-fat meal. Engaging in hazardous activities that require concentration (such as operating a motor vehicle or heavy machinery) after taking this medication should be avoided.
The most common adverse events seen with this medication that had greater than 2% incidence difference from placebo were somnolence, dizziness, and fatigue.
Rozerem should not be used in combination with fluvoxamine.